FDA OKs diabetes drug combo Jentadueto

01/30/2012 | Wall Street Journal, The

Eli Lilly and Co. and Boehringer Ingelheim received FDA approval for Jentadueto, a type 2 diabetes medicine intended for use with exercise and diet. The oral treatment, which combines linagliptin and metformin hydrochloride, can be taken alone or with commonly prescribed sulfonylurea.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ